Insulin Aspart is a rapid-acting human insulin analogue produced by recombinant DNA technology in Saccharomyces cerevisiae (baker's yeast). It is chemically identical to human insulin except for a substitution of the amino acid proline with aspartic acid at position B28. This modification reduces the molecule's tendency to form hexamers, allowing for faster dissociation into monomers and thus a more rapid absorption and onset of action compared to regular human insulin. It is used to control hyperglycemia in patients with diabetes mellitus.
Adult: Highly individualized. Typically administered 0-15 minutes before a meal. The total daily insulin requirement (TDD) varies but often ranges from 0.5 to 1.0 IU/kg/day. In a basal-bolus regimen, Insulin Aspart typically provides 50-70% of TDD, divided as pre-meal bolus doses. Starting dose in insulin-naïve patients with Type 2 DM: often 4-6 IU before main meals, adjusted based on pre-meal and postprandial glucose.
Note: For subcutaneous injection into abdominal wall, thigh, buttock, or upper arm. Rotate injection sites within the same region. Inject 0-15 minutes BEFORE a meal. Use appropriate insulin syringe (100 IU/ml) or pen device. Do not mix with other insulins in the same syringe unless specifically indicated (e.g., with NPH). If mixing, draw Insulin Aspart into syringe first. Do not administer intravenously outside clinical settings.
Insulin Aspart binds to the alpha-subunit of the insulin receptor (a transmembrane tyrosine kinase receptor) on target cells (primarily liver, muscle, and adipose tissue). This binding activates the receptor's intrinsic tyrosine kinase activity, leading to autophosphorylation and recruitment/phosphorylation of intracellular substrate proteins (e.g., IRS-1/2). This triggers a cascade of signaling pathways (PI3K-Akt and MAPK pathways) that mediate insulin's metabolic and growth-promoting effects.
Pregnancy: Pregnancy Category B (US FDA). Considered safe and is the preferred rapid-acting insulin for use during pregnancy (both pre-gestational and gestational diabetes). Insulin requirements may decrease in first trimester and increase significantly in second/third trimesters. Close monitoring of glucose is essential.
Driving: Patients must be aware of the risk of hypoglycemia impairing concentration and reaction time. Blood glucose should be checked before driving and during long journeys. Carry fast-acting carbohydrates.
| Oral Hypoglycemic Agents (Sulfonylureas, Meglitinides) | Additive hypoglycemic effect, increased risk of hypoglycemia | Major |
| Corticosteroids (e.g., Prednisolone, Dexamethasone) | Antagonize insulin effect, cause hyperglycemia, requiring dose increase | Major |
| Beta-blockers (e.g., Propranolol) | May mask tachycardia of hypoglycemia, impair recovery from hypoglycemia | Moderate |
| Thiazide Diuretics (e.g., Hydrochlorothiazide) | May cause hyperglycemia, reducing insulin efficacy | Moderate |
| ACE Inhibitors (e.g., Ramipril) | May enhance insulin sensitivity, increasing hypoglycemia risk | Moderate |
| Alcohol | Acute intake can increase hypoglycemia risk (impairs gluconeogenesis); chronic intake can cause hyperglycemia | Major |
| Octreotide, Lanreotide | Alters glucose metabolism, may require insulin dose adjustment | Moderate |
| MAO Inhibitors, Anabolic Steroids | Increase hypoglycemic effect | Moderate |
Same composition (Insulin Aspart (100IU/ml)), different brands: